Bacteria:Article Title: Model-based quantification of immune response and anti-staphylococcal activity of afabicin in immunocompetent mouse thigh infections to enable predictions of clinical efficacy.
Article Snippet: .. Bacterial dynamics kgrowth Bacteria growth rate constant h −1 1.10 (Fixed) kdeath Bacteria natural death rate constant h −1 0.179 (Fixed) Bmax vitro Maximum system capacity – in vitro log10 CFU/mL 9.86 (Fixed) Bmax vivo Maximum system capacity – in vivo log10 CFU/g 9.08 (Fixed) RESvitro a Residual variability – in vitro log10 CFU/mL 0.877 (4.9) RESvivo a Residual variability – in vivo log10 CFU/g 0.555 (4.2) Immune response F33591 Inoculum bioavailability in immunocompetent mice (S. aureus ATCC 33591) –c 0.437 (6.2) Ncirc,T0 Baseline circulating neutrophil count log10 N/mL 6.23 (Fixed) MTT Neutrophil maturation mean transit time h 37.7 (Fixed) Namp Surge amplitude – 44.2 (Fixed) NT0 Surge peak time h 50.5 (Fixed) NSW Surge width h 28.2 (Fixed) kphag,max Maximum phagocytosis rate constant b h−1 0.963 (2.0) kdig Digestion rate constant b P/N50 Phagocytosed bacteria to neutrophil count ratio reducing the phagocytosis rate by 50% CFU/N 114 (16) H Saturation sigmoidicity factor – 0.475 (12) Afabicin desphosphono effect Emax vitro Maximum afabicin desphosphono killing rate constant – in vitro h−1 2.99 (5.2) RatioEmax Ratio for Emax in vivo (Emax vivo = Emax vitro • RatioEmax) – 0.0796 (9.3) βvitro EC50 scaling slope – in vitro – 1 (Fixed) βvivo EC50 scaling slope – in vivo – 0.182 (16) γ EC50 scaling power (EC50 = β • MIC γ) – 0.185 (24) Hill Emax model sigmoidicity factor – 0.515 (7.4) kon Adaptation onset rate constant mL/ (μg•h) 0.556 (25) koff Adaptation offset rate constant h −1 0.0139 (Fixed) AS50 Fraction needed to reach 50% of reduction in Emax – 0.784 (10) aRES parameters correspond to the magnitude of residual unexplained variability on the standard deviation scale. bParameters sharing the same estimate. c–, unitless parameters. ..
In Vitro:Article Title: Model-based quantification of immune response and anti-staphylococcal activity of afabicin in immunocompetent mouse thigh infections to enable predictions of clinical efficacy.
Article Snippet: .. Bacterial dynamics kgrowth Bacteria growth rate constant h −1 1.10 (Fixed) kdeath Bacteria natural death rate constant h −1 0.179 (Fixed) Bmax vitro Maximum system capacity – in vitro log10 CFU/mL 9.86 (Fixed) Bmax vivo Maximum system capacity – in vivo log10 CFU/g 9.08 (Fixed) RESvitro a Residual variability – in vitro log10 CFU/mL 0.877 (4.9) RESvivo a Residual variability – in vivo log10 CFU/g 0.555 (4.2) Immune response F33591 Inoculum bioavailability in immunocompetent mice (S. aureus ATCC 33591) –c 0.437 (6.2) Ncirc,T0 Baseline circulating neutrophil count log10 N/mL 6.23 (Fixed) MTT Neutrophil maturation mean transit time h 37.7 (Fixed) Namp Surge amplitude – 44.2 (Fixed) NT0 Surge peak time h 50.5 (Fixed) NSW Surge width h 28.2 (Fixed) kphag,max Maximum phagocytosis rate constant b h−1 0.963 (2.0) kdig Digestion rate constant b P/N50 Phagocytosed bacteria to neutrophil count ratio reducing the phagocytosis rate by 50% CFU/N 114 (16) H Saturation sigmoidicity factor – 0.475 (12) Afabicin desphosphono effect Emax vitro Maximum afabicin desphosphono killing rate constant – in vitro h−1 2.99 (5.2) RatioEmax Ratio for Emax in vivo (Emax vivo = Emax vitro • RatioEmax) – 0.0796 (9.3) βvitro EC50 scaling slope – in vitro – 1 (Fixed) βvivo EC50 scaling slope – in vivo – 0.182 (16) γ EC50 scaling power (EC50 = β • MIC γ) – 0.185 (24) Hill Emax model sigmoidicity factor – 0.515 (7.4) kon Adaptation onset rate constant mL/ (μg•h) 0.556 (25) koff Adaptation offset rate constant h −1 0.0139 (Fixed) AS50 Fraction needed to reach 50% of reduction in Emax – 0.784 (10) aRES parameters correspond to the magnitude of residual unexplained variability on the standard deviation scale. bParameters sharing the same estimate. c–, unitless parameters. ..
In Vivo:Article Title: Model-based quantification of immune response and anti-staphylococcal activity of afabicin in immunocompetent mouse thigh infections to enable predictions of clinical efficacy.
Article Snippet: .. Bacterial dynamics kgrowth Bacteria growth rate constant h −1 1.10 (Fixed) kdeath Bacteria natural death rate constant h −1 0.179 (Fixed) Bmax vitro Maximum system capacity – in vitro log10 CFU/mL 9.86 (Fixed) Bmax vivo Maximum system capacity – in vivo log10 CFU/g 9.08 (Fixed) RESvitro a Residual variability – in vitro log10 CFU/mL 0.877 (4.9) RESvivo a Residual variability – in vivo log10 CFU/g 0.555 (4.2) Immune response F33591 Inoculum bioavailability in immunocompetent mice (S. aureus ATCC 33591) –c 0.437 (6.2) Ncirc,T0 Baseline circulating neutrophil count log10 N/mL 6.23 (Fixed) MTT Neutrophil maturation mean transit time h 37.7 (Fixed) Namp Surge amplitude – 44.2 (Fixed) NT0 Surge peak time h 50.5 (Fixed) NSW Surge width h 28.2 (Fixed) kphag,max Maximum phagocytosis rate constant b h−1 0.963 (2.0) kdig Digestion rate constant b P/N50 Phagocytosed bacteria to neutrophil count ratio reducing the phagocytosis rate by 50% CFU/N 114 (16) H Saturation sigmoidicity factor – 0.475 (12) Afabicin desphosphono effect Emax vitro Maximum afabicin desphosphono killing rate constant – in vitro h−1 2.99 (5.2) RatioEmax Ratio for Emax in vivo (Emax vivo = Emax vitro • RatioEmax) – 0.0796 (9.3) βvitro EC50 scaling slope – in vitro – 1 (Fixed) βvivo EC50 scaling slope – in vivo – 0.182 (16) γ EC50 scaling power (EC50 = β • MIC γ) – 0.185 (24) Hill Emax model sigmoidicity factor – 0.515 (7.4) kon Adaptation onset rate constant mL/ (μg•h) 0.556 (25) koff Adaptation offset rate constant h −1 0.0139 (Fixed) AS50 Fraction needed to reach 50% of reduction in Emax – 0.784 (10) aRES parameters correspond to the magnitude of residual unexplained variability on the standard deviation scale. bParameters sharing the same estimate. c–, unitless parameters. ..
MTT Assay:Article Title: Model-based quantification of immune response and anti-staphylococcal activity of afabicin in immunocompetent mouse thigh infections to enable predictions of clinical efficacy.
Article Snippet: .. Bacterial dynamics kgrowth Bacteria growth rate constant h −1 1.10 (Fixed) kdeath Bacteria natural death rate constant h −1 0.179 (Fixed) Bmax vitro Maximum system capacity – in vitro log10 CFU/mL 9.86 (Fixed) Bmax vivo Maximum system capacity – in vivo log10 CFU/g 9.08 (Fixed) RESvitro a Residual variability – in vitro log10 CFU/mL 0.877 (4.9) RESvivo a Residual variability – in vivo log10 CFU/g 0.555 (4.2) Immune response F33591 Inoculum bioavailability in immunocompetent mice (S. aureus ATCC 33591) –c 0.437 (6.2) Ncirc,T0 Baseline circulating neutrophil count log10 N/mL 6.23 (Fixed) MTT Neutrophil maturation mean transit time h 37.7 (Fixed) Namp Surge amplitude – 44.2 (Fixed) NT0 Surge peak time h 50.5 (Fixed) NSW Surge width h 28.2 (Fixed) kphag,max Maximum phagocytosis rate constant b h−1 0.963 (2.0) kdig Digestion rate constant b P/N50 Phagocytosed bacteria to neutrophil count ratio reducing the phagocytosis rate by 50% CFU/N 114 (16) H Saturation sigmoidicity factor – 0.475 (12) Afabicin desphosphono effect Emax vitro Maximum afabicin desphosphono killing rate constant – in vitro h−1 2.99 (5.2) RatioEmax Ratio for Emax in vivo (Emax vivo = Emax vitro • RatioEmax) – 0.0796 (9.3) βvitro EC50 scaling slope – in vitro – 1 (Fixed) βvivo EC50 scaling slope – in vivo – 0.182 (16) γ EC50 scaling power (EC50 = β • MIC γ) – 0.185 (24) Hill Emax model sigmoidicity factor – 0.515 (7.4) kon Adaptation onset rate constant mL/ (μg•h) 0.556 (25) koff Adaptation offset rate constant h −1 0.0139 (Fixed) AS50 Fraction needed to reach 50% of reduction in Emax – 0.784 (10) aRES parameters correspond to the magnitude of residual unexplained variability on the standard deviation scale. bParameters sharing the same estimate. c–, unitless parameters. ..
Standard Deviation:Article Title: Model-based quantification of immune response and anti-staphylococcal activity of afabicin in immunocompetent mouse thigh infections to enable predictions of clinical efficacy.
Article Snippet: .. Bacterial dynamics kgrowth Bacteria growth rate constant h −1 1.10 (Fixed) kdeath Bacteria natural death rate constant h −1 0.179 (Fixed) Bmax vitro Maximum system capacity – in vitro log10 CFU/mL 9.86 (Fixed) Bmax vivo Maximum system capacity – in vivo log10 CFU/g 9.08 (Fixed) RESvitro a Residual variability – in vitro log10 CFU/mL 0.877 (4.9) RESvivo a Residual variability – in vivo log10 CFU/g 0.555 (4.2) Immune response F33591 Inoculum bioavailability in immunocompetent mice (S. aureus ATCC 33591) –c 0.437 (6.2) Ncirc,T0 Baseline circulating neutrophil count log10 N/mL 6.23 (Fixed) MTT Neutrophil maturation mean transit time h 37.7 (Fixed) Namp Surge amplitude – 44.2 (Fixed) NT0 Surge peak time h 50.5 (Fixed) NSW Surge width h 28.2 (Fixed) kphag,max Maximum phagocytosis rate constant b h−1 0.963 (2.0) kdig Digestion rate constant b P/N50 Phagocytosed bacteria to neutrophil count ratio reducing the phagocytosis rate by 50% CFU/N 114 (16) H Saturation sigmoidicity factor – 0.475 (12) Afabicin desphosphono effect Emax vitro Maximum afabicin desphosphono killing rate constant – in vitro h−1 2.99 (5.2) RatioEmax Ratio for Emax in vivo (Emax vivo = Emax vitro • RatioEmax) – 0.0796 (9.3) βvitro EC50 scaling slope – in vitro – 1 (Fixed) βvivo EC50 scaling slope – in vivo – 0.182 (16) γ EC50 scaling power (EC50 = β • MIC γ) – 0.185 (24) Hill Emax model sigmoidicity factor – 0.515 (7.4) kon Adaptation onset rate constant mL/ (μg•h) 0.556 (25) koff Adaptation offset rate constant h −1 0.0139 (Fixed) AS50 Fraction needed to reach 50% of reduction in Emax – 0.784 (10) aRES parameters correspond to the magnitude of residual unexplained variability on the standard deviation scale. bParameters sharing the same estimate. c–, unitless parameters. ..
|
ATCC is a verified supplier 
ATCC manufactures this product 